Chul Kim

2 months ago | mdpi.com | Chul Kim |Hee-Eun Choi |Chin Kook Rhee |Jae Lee

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

May 20, 2024 | journals.plos.org | Yeji Kim |Chul Kim |Jong Woo Kim

Citation: Kim Y, Kim CG, Kim JW, Han K, Kim JH (2024) Cumulative effect of metabolic syndrome on the risk of retinal vein occlusion in young patients: A nationwide population-based study. PLoS ONE 19(5): e0303871. https://doi.org/10.1371/journal.pone.0303871Editor: Jiro Kogo, Akita University: Akita Daigaku, JAPANReceived: August 8, 2023; Accepted: May 1, 2024; Published: May 20, 2024Copyright: © 2024 Kim et al.

Apr 3, 2024 | mdpi.com | Chul Kim |Chin Kook Rhee |Jun Song |Hee-Eun Choi

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Feb 22, 2024 | onclive.com | Chul Kim

Chul Kim, MD, MPH, thoracic oncologist, associate professor, medical oncology, Georgetown University Lombardi Comprehensive Cancer Center, MedStar Health, discusses the impact of optimizing rare targets in non–small cell lung cancer (NSCLC), such as ROS1 and ALK, highlighting the FDA approval of repotrectinib (Augtyro) in ROS1-positive disease. Previously, the NSCLC treatment armamentarium included 2 ROS1 TKIs: crizotinib (Xalkori) and entrectinib (Rozlytrek), Kim begins.

Dec 14, 2023 | dx.doi.org | Junwoo Kim |Hyun Lee |Chul Kim

Download Hi-Res ImageDownload to MS-PowerPointCite This:J. Phys. Chem. B 2024, XXXX, XXX Terms & Conditions Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses).